VOCABRIA SIDE EFFECTS
- Generic Name: cabotegravir tablets for oral use
- Brand Name: Vocabria
- Drug Class: HIV, Integrase Inhibitors
SIDE EFFECTS
The following adverse reactions are described below and in other sections of the labeling:
- Hypersensitivity reactions
- Hepatotoxicity
- Depressive disorders
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect rates observed in practice. See full prescribing information for CABENUVA for additional safety information. Since VOCABRIA is taken in combination with EDURANT tablets, the prescribing information for EDURANT should be consulted for relevant information on rilpivirine.
Adverse Reactions Of VOCABRIA In Clinical Trials For The Treatment Of HIV-1 Infection
The safety assessment of VOCABRIA for oral lead-in therapy prior to therapy with CABENUVA is based on the analysis of 48-week data from virologically suppressed subjects with HIV-1 infection in 3 international, multicenter, open-label trials, which 590 of 1,182 subjects received oral lead-in, from the pivotal trials FLAIR and ATLAS (pooled analysis) and 655 of 1,045 subjects received oral lead-in, from ATLAS-2M.
Adverse reactions were reported following exposure to VOCABRIA tablets and EDURANT tablets administered in combination as oral lead-in therapy (median time exposure: 5.3 weeks). Adverse reactions included those attributable to the oral formulation of cabotegravir and rilpivirine administered as a combination regimen. Refer to the prescribing information for EDURANT for other adverse reactions associated with oral rilpivirine.
The most common adverse reactions during the oral lead-in period for FLAIR and ATLAS were headache, nausea, abnormal dreams, anxiety, and insomnia, all of which occurred in at least 3 subjects with an incidence ≤1%. The most common adverse reactions during the oral lead-in period for ATLAS-2M were fatigue, diarrhea, headache, nausea, dizziness, abdominal discomfort, abdominal distension, insomnia, and asthenia, all of which occurred in at least 3 subjects across both arms, with an incidence ≤2%.
During the oral lead-in period for FLAIR and ATLAS, 6 (1%) subjects discontinued due to adverse events, including asthenia, myalgia, depression suicidal, and headache. During the oral lead-in period for ATLAS-2M, 4 (<1%) subjects discontinued due to adverse events, including asthenia, skin lesion, fatigue, transaminases increased, and depression.
Adverse Reactions Of VOCABRIA In HPTN 083 Trial For HIV-1 PrEP
Adverse reactions were reported while on blinded study product following exposure to VOCABRIA tablets as oral lead-in for HIV-1 PrEP (median time exposure: 4.1 weeks). The most common adverse reactions reported at ≥1% during the oral lead-in period were diarrhea (4% and 4%), nausea (3% and 5%), dizziness (2% and 2%), headache (2% and 2%), fatigue (1% and 2%), and abnormal dreams (1% and 2%) for VOCABRIA and TRUVADA (emtricitabine and tenofovir disoproxil fumarate), respectively. During the oral lead-in period, 24 (1%) participants receiving VOCABRIA discontinued due to adverse events, including increased alanine aminotransferase, increased aspartate aminotransferase, suicide attempt, and dizziness, which were observed in ≥2 participants.
Adverse Reactions Of VOCABRIA In HPTN 084 Trial For HIV-1 PrEP
Adverse reactions reported while on blinded study product following exposure to VOCABRIA tablets as oral lead-in for HIV-1 PrEP (median time exposure: 4.1 weeks). The most common adverse reactions reported at ≥1% during the oral lead-in period were headache (6% and 7%), nausea (3% and 7%), dizziness (3% and 4%), diarrhea (2% and 4%), upper respiratory tract infection (2% and 2%), somnolence (2% and 1%), fatigue (1% and 2%), abdominal pain (1% and 1%), vomiting (<1% and 3%), decreased appetite (<1% and 2%), and pruritus (<1% and 1%) for VOCABRIA and TRUVADA, respectively. During the oral lead-in period, 4 (<1%) participants receiving VOCABRIA discontinued due to adverse events of increased alanine aminotransferase (n = 3) and sleep disorders (n = 1).
Clinical Trials Experience In Adolescents
In adolescents receiving VOCABRIA for HIV-1 PrEP, the safety data were comparable to the safety data reported in adults receiving VOCABRIA for HIV-1 PrEP.
SRC: NLM .